ArticleJournal of asthma and allergy2026
Stability of Type 2 Inflammation in a 12-Year Adult-Onset Asthma Follow-Up Study.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the stability of T2 inflammation and clinical features associated with high or low T2 markers in adult-onset asthma. Patients and Methods: Seinäjoki Adult Asthma Study is a 12-year follow-up study including 256 patients diagnosed with new-onset adult asthma. Patients were grouped according to T2 marker status at baseline when steroid-naïve and at the 12-year follow-up after long-term inhaled corticosteroid (ICS) treatment. High T2 markers were defined at diagnosis by ≥1 of the following: blood eosinophils ≥0.30×10 Results: At diagnosis, 109 patients (66.5%) had high and 55 (33.5%) low T2 markers. Low T2 marker patients were older, had higher BMI, and higher Airway Questionnaire 20 scores. High T2 marker patients had greater reversibility of forced expiratory volume in 1 second. At follow-up, baseline low T2 marker patients had more comorbidities, non-respiratory medications and lower Asthma Control Test scores. Of patients, 76% remained in the low T2 marker group and 24% transitioned to the high T2 marker group; those who transitioned had higher BMI. Sixty-eight percent remained in the high T2 marker group and 32% transitioned to the low T2 marker group; those who transitioned were older, had more comorbidities, and more non-respiratory medications. No significant differences were observed between patients who transitioned and those remaining stable regarding lung function, asthma severity, control, exacerbations, or ICS use. Conclusion: T2 high and low markers of adult-onset asthma are largely stable over time. However, differences in comorbidities, non-respiratory medication, age, and BMI distinguish the groups significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.